Established Facts
• Mutations in the hepatocyte nuclear factor-4 alpha (HNF4A) are responsible for maturity-onset diabetes of the young and congenital hyperinsulinism.
• Recently, the HNF4A phenotypic spectrum has been expanded to include atypical renal Fanconi syndrome, specifically linked to the p.R63W mutation.
• So far, only 7 patients with this mutation have been reported, all of them being macrosomic at birth.
Novel Insights
• We extend the previous observations and present 2 patients with the p.R63W mutation, 1 of them having a birth weight (BW) appropriate for his gestational age, and the other having signs of liver involvement.
• Our cases suggest that HNF4A mutations must be considered also in the presence of a normal BW and that liver involvement is probably part of this condition.
Introduction
Congenital hyperinsulinism (CHI) is characterized by hypoglycaemia caused by unregulated insulin secretion from pancreatic beta cells. So far, mutations in nine genes, which control the insulin secretion ( ABCC8, KCNJ11, GLUD1, GCK, HNF4A, HNF1A, SLC16A1, UCP2 and HADH ) have been identified as a cause of CHI [1] . However, mutations in a single gene may be responsible for different phenotypes. Recent studies demonstrate that mutations in the hepatocyte nuclear factor-4 alpha ( HNF4A; encoded by the HNF4A gene), initially reported in patients with maturity-onset diabetes of the young (MODY), may conversely cause CHI, with variable degrees of severity [2, 3] . Recent reports [4, 5] indicate a mutation-specific phenotype associated with the p.R63W mutation in the HNF4A gene, with macrosomic CHI and proximal renal tubular dysfunction. We now extend the previous observations and present 2 patients with the p.R63W mutation, one of them having a birth weight (BW) appropriate for his gestational age, and the other having signs of liver involvement.
Case Series
Case 1, a male, was born at 38 weeks + 2 days, with a BW of 3.99 kg (95th centile, SDS 1.7). On day 2, he presented with hypoglycaemic seizures (undetectable blood glucose). Initial investigations showed polycythaemia (haemoglobin 26.2 g/dl, haematocrit 76%), deranged renal function (creatinine 119 μmol/l, potassium 5.9 mmol/l), conjugated hyperbilirubinaemia (146 μmol/l), metabolic acidosis (ph 7.3, PCO2 4.73 kPa, HCO 3 21.3 mmol/l, BE 4.5 mmol/l) and Staphylococcus aureus sepsis. Despite the patient's response to antibiotics and resolution of polycythaemia, he continued having a glucose requirement of up to 18.9 mg/kg/min. A hypoglycaemia screen confirmed hyperinsulinaemic hypoglycaemia (HI) ( table 1 ). The patient initially achieved stable blood glucose concentrations on 3 mg/kg/day of diazoxide. Because of the persistently raised serum creatinine and high urine amino acids, he had a renal tubular screen done, showing features of proximal renal tubular dysfunction ( table 1 ) . Abdominal ultrasound revealed normal kidneys and patchy liver steatosis. Conjugated bilirubin normalized with ursodeoxycholic acid treatment. He was heterozygote for the de novo c.187C>T (p.R63W) mutation in HNF4A . The patient is currently 10 months old and is stable on 10 mg/kg/day of diazoxide and three-to-four hourly oral feeds (fasting tolerance 4.5 h).
Case 2, a male, was born at 30 weeks + 2 days by emergency caesarean section. BW was 1.53 kg (64th centile, SDS 0.36). On day 1 of life, the child was commenced on parenteral nutrition because of suspected necrotizing enterocolitis. While establishing enteral feeds at the corrected age of 34 weeks, he presented with hypoglycaemia episodes (minimum blood glucose 1.6 mmol/l). Biochemistry workup at the time of hypoglycaemia confirmed HI and revealed low calcium, sodium and phosphate concentrations. A renal tubular screen showed signs of proximal renal tubular dysfunction ( table 1 ) . Ultrasound of the kidneys was normal. The patient has achieved good glycaemic control on regular oral feeds and 2 mg/kg/day of diazoxide, with a fasting tolerance of 3.5 h. Molecular analysis showed a p.R63W mutation in HNF4A . This patient died from an unknown cause at the age of 7 months but was still on diazoxide therapy.
His mother (BW SDS 2.1) had been diagnosed with renal Fanconi syndrome at the age of 2 years because of hypophosphataemic rickets (tubular reabsorption of phosphates 47%) and proteinuria (urine N-acetylglucosamine/creatinine ratio 88 U/mmol, normal range 2-12; urine retinol-binding protein/creatinine ratio 27,174 μg/mmol, normal range 3.9-32). Molecular analysis of HNF4A, performed after the diagnosis was established in her son, confirmed that she was a carrier of the p.R63W mutation. Subsequently, she underwent continuous glucose monitoring ( fig. 1 ) , which revealed prolonged overnight hypoglycaemia and post-prandial hyperglycaemia.
Discussion
Our clinical observations in these 2 patients expand the clinical phenotypes associated with HNF4A mutations. HNF4 A mutation is the third commonest cause of diazoxide-responsive CHI [1] , usually associated with early presentation and macrosomia [3] . Mutations in this gene may also be responsible for MODY later on in life, and interestingly, a single mutation can cause opposite phenotypes (CHI and MODY) in the same subject, according to the age [6] . However, the penetrance of each phenotype is incomplete, and thus the absent history of neonatal HI in a subject with MODY or, on the other hand, the absence of any family history of diabetes in patients with CHI, does not exclude the diagnosis. A similar biphasic phenotype (HI-MODY) was initially described in patients carrying mutations in HNF1A [1] , which is involved in the transcription of HNF4A through the pancreatic-specific promoter P2, and is in turn regulated by HNF4A [7] . The pathophysiological basis of this peculiar evolution of the phenotype is still unclear. In this regard, it is worth to point out that, although data on insulin are not available, the continuous glucose monitoring system applied in the mother of case 2 ( fig. 1 ) showed prolonged overnight hypoglycaemia and post-prandial hyperglycaemia, thus providing evidence of dysregulation of insulin secretion. A role of tubular dysfunction on disrupted glycaemic control might also be postulated.
The HNF4A phenotypic spectrum has recently been expanded to include proximal renal tubular dysfunction characterized by renal tubular leaking of phosphate, proteins, bicarbonates, glucose, calcium and magnesium (previously named atypical renal Fanconi syndrome), specifically linked to the p.R63W mutation [4, 5] . Our cases provide further evidence of a mutation-specific renal phenotype and extend the previous observations, arising important clinical considerations. The molecular basis and the pathogenesis of tubular dysfunction in patients carrying the p.R63W mutation in HNF4A are far from clear but seem to involve an impaired DNA binding. In fact, the R63 residue is in the DNA-binding domain, and its mutation affects charge and hydrophobicity in an area of intimate DNA contact. It has been hypothesized that this specific residue must be crucial in the renal proximal tubule [4, 5] .
Another possible explanation is to be sought into the intimate relationship between HNF4A, HNF1A and other regulatory proteins. Heterozygote knockout mice for either HNF4A or HNF1A have no distinct phenotype. On the contrary, although the homozygous knockout of HNF4A is lethal, mice with homozygous knockout of HNF1A [8] exhibit hepatic dysfunction, phenylketonuria and early-onset renal Fanconi syndrome associated with a raised urine calcium/creatinine ratio and reduced creatinine clearance.
Given that HNF4A and HNF1A are involved in a feedforward loop, it could be speculated that haploinsufficiency of HNF4A can have an impact on HNF1A , resulting in specific organ damage. Other genetic factors within the wide regulatory network of HNF4A are probably involved. Both HNF4A and HNF1A can regulate the expression of glucose transporter 2 (GLUT2, SLC2A2 ), which is responsible, if mutated, for Fanconi-Bickel syndrome [9] . Stanescu et al. [5] first reported a macrosomic female patient with diazoxide-responsive CHI and proximal renal tubular dysfunction due to a de novo p.R63W HNF4A mutation (described as p.R76W) who also presented with liver involvement, thus mimicking FanconiBickel syndrome. Late liver involvement characterized by hepatomegaly and persistent hypertransaminasaemia has also been recently reported in another patient with CHI due to the p.R63W HNF4A mutation [10] . In this regard, it is worth noting that in case 1 from our case series, we observed prolonged conjugated hyperbilirubinaemia, which normalized over the first 3 months of life on ursodeoxycholic acid, and patchy liver steatosis. In order to explain the clinical overlap between an HNF4A mutationspecific phenotype and Fanconi-Bickel syndrome, a decreased expression of SLC2A2 either as a direct consequence of HNF4A impairment or as a result of the impaired interaction between the mutant HNF4A and HNF1A can be hypothesized [5] .
The absence of nephrocalcinosis in our cases compared to the others could be explained by the short follow-up. High urine magnesium may be due to overflow rather than leaking, as suggested by high serum magnesium concentrations [4] .
Although all cases reported with this specific mutation were born large for gestational age [11] , interestingly, case 2 from our case series had a BW appropriate to his gestational age. Given that his mother had a similar genotype and an abnormal glycaemic profile, it is possible that in utero, the foetus had been exposed to blood glucose concentrations appropriate for his own set-point for insulin secretion, resulting in lower insulin concentrations. Prematurity and/or placental factors might also have contributed.
Conclusion
Knowledge of the genetics of CHI allows the prediction of disease progression and comorbidities. Proximal renal tubular dysfunction represents the only HNF4A feature with complete penetrance, being present in all patients reported carrying the p.R63W mutation. The underlying mechanisms are unclear and probably involve an impaired HNF4A regulatory network, resulting in tubular dysfunction. Our cases suggest that HNF4A mutations should be considered also in the presence of a normal BW. Transient or permanent liver involvement may be part of this condition, and therefore awareness about the possibility of associated diseases is needed during the follow-up of HNF4A -mutation carriers.
